Raymond James & Associates’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-11,217
| Closed | -$38K | – | 3797 |
|
|
2018
Q3 | $38K | Sell |
11,217
-1,454
| -11% | -$5.24K | ﹤0.01% | 3507 |
|
|
2018
Q2 | $48K | Buy |
12,671
+500
| +4% | +$2.43K | ﹤0.01% | 3442 |
|
|
2018
Q1 | $50K | Sell |
12,171
-3,216
| -21% | -$15K | ﹤0.01% | 3323 |
|
|
2017
Q4 | $72K | Buy |
15,387
+1,615
| +12% | +$8.9K | ﹤0.01% | 3251 |
|
|
2017
Q3 | $98K | Sell |
13,772
-719
| -5% | -$5.17K | ﹤0.01% | 3184 |
|
|
2017
Q2 | $105K | Sell |
14,491
-10,410
| -42% | -$65K | ﹤0.01% | 3107 |
|
|
2017
Q1 | $153K | Buy |
24,901
+12,996
| +109% | +$71.2K | ﹤0.01% | 2997 |
|
|
2016
Q4 | $70K | Sell |
11,905
-2,537
| -18% | -$13.9K | ﹤0.01% | 3068 |
|
|
2016
Q3 | $77K | Buy |
14,442
+2,128
| +17% | +$11.5K | ﹤0.01% | 3036 |
|
|
2016
Q2 | $82K | Sell |
12,314
-212
| -2% | -$1.19K | ﹤0.01% | 2841 |
|
|
2016
Q1 | $58K | Buy |
+12,526
| New | +$50K | ﹤0.01% | 2777 |
|
|
2015
Q2 | – | Sell |
-19,624
| Closed | -$250K | – | 2479 |
|
|
2015
Q1 | $250K | Buy |
19,624
+2,235
| +13% | +$28.7K | ﹤0.01% | 2265 |
|
|
2014
Q4 | $246K | Buy |
+17,389
| New | +$269K | ﹤0.01% | 2177 |
|
Raymond James & Associates's KERX Position: Q4 2018 in Review
Raymond James & Associates sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 11,217 shares — an estimated $38K sold.
Raymond James & Associates first reported a position in KERX in Q4 2014 and held it in 13 quarters. The position peaked at $250K in Q1 2015. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Raymond James & Associates reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Raymond James & Associates sold 11,217 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $38K.
- Raymond James & Associates first reported a position in Keryx Biopharmaceuticals Inc in Q4 2014 and held it in 13 quarters.
- Raymond James & Associates's Keryx Biopharmaceuticals Inc position peaked at $250K in Q1 2015.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Raymond James & Associates's 13F filing for Q4 2018, filed 11 Feb 2019.